The 77th-ranked Majchrzak, who won the Challenger Tour event in
Busan, South Korea in October and reached the semi-finals of an
ATP 250 event in Pune, India earlier this year, did not provide
further details about the banned substance.
The ITIA said on Friday that Majchrzak had provided samples from
tournaments at Sofia in September and Japan and Seoul in October
which were found to contain three banned substances (SARM S-22,
LGD-4033 and PPARδ agonists).
"I have some incredibly sad and difficult news to share with
everyone. I have tested positive in anti-doping controls during
October and November 2022," Majchrzak wrote in a post on
Instagram on Thursday.
"Firstly, I have never, ever, knowingly taken any banned
substance. At this moment I have no idea what has happened and
this is the biggest shock.
"I have started the most difficult fight of my life -- the fight
to prove my innocence and to return to the sport I love."
The ITIA said the player can request that his B samples are
analysed to see if they confirm the A sample findings.
"While provisionally suspended, he is ineligible to compete in
or attend any sanctioned tennis events organised by the
governing bodies of the sport," the ITIA said.
(Reporting by Aadi Nair in Bengaluru; Editing by Ken Ferris)
[© 2022 Thomson Reuters. All rights
reserved.]
This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
|